Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone

Journal of Clinical Psychiatry

Volumn 72, Issue 3, 2011, Pages 367-375

  Karayal, Onur N ^a   Anway, Susan D ^a   Batzar, Evan ^a   Vanderburg, Douglas G ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE; SERTRALINE; TOPIRAMATE; ZIPRASIDONE;

ADULT; ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CHILD; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GILLES DE LA TOURETTE SYNDROME; HUMAN; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; PARANOID SCHIZOPHRENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TREATMENT DURATION; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; CONFIDENCE INTERVALS; HUMANS; ODDS RATIO; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SCHIZOPHRENIA; SUICIDAL IDEATION; SUICIDE; SUICIDE, ATTEMPTED; THIAZOLES;

EID: 79953050804     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06281gre     Document Type: Article

References (59)

1. Dutta R, Boydell J, Kennedy N, et al. Suicide and other causes of mortality in bipolar disorder: a longitudinal study. Psychol Med. 2007;37(6): 839-847. doi:10.1017/S032917070347 PubMed (Pubitemid 46746328)
2. Heilä H, Isometsä ET, Henriksson MM, et al. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry. 1997;154(9):1235-1242. PubMed
3. Meltzer HY. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep. 2002; 4(4):279-283. doi:10.107/s1920-96-047-6 PubMed
4. Pompili M, Amador XF, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry. 2007; 6(1):10. doi:10.186/174-859X-6-10 PubMed
5. Sharma V. Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disord. 2003;5(suppl 2):48-52. doi:10.1/j.139-2406.203.062.x PubMed (Pubitemid 38444337)
6. Tandon R. Suicidal behavior in schizophrenia. Expert Rev Neurother. 2005;5(1):95-99. doi:10.1586/14737175.5.1.95 PubMed (Pubitemid 40127689)
7. Khalsa HM, Salvatore P, Hennen J, et al. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J Affect Disord. 2008;106(1-2):179-184. doi:10.1016/j.jad.207.05.027 PubMed
8. Barak Y, Mirecki I, Knobler HY, et al. Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl). 2004;175(2): 215-219. doi:10.107/s0213-04-1801-2 PubMed (Pubitemid 39222352)
9. Aguilar EJ, Siris SG, Leal C. Can atypical antipsychotics reduce suicide risk in patients with schizophrenia? an evidence-based analysis. Psychiatric Times. 2008;25(5):15.
10. Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000; 61(suppl 3):4-9. PubMed
11. Haukka J, Tiihonen J, Härkänen T, et al. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008;17(7):686-696. doi:10.102/pds.1579 PubMed
12. Ward A, Ishak K, Proskorovsky I, et al. Compliance with refilling zprescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther. 2006;28(11):1912-1921. doi:10.1016/j.clinthera.206.1.02 PubMed (Pubitemid 46038522)
13. Houston JP, Ahl J, Meyers AL, et al. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006; 67(8):1246-1252. doi:10.408/JCP.v67n081 PubMed (Pubitemid 44439697)
14. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am J Psychiatry. 2001;158(9):1449-1454. doi:10.176/api.ajp.158.9.149 PubMed (Pubitemid 32847244)
15. Storosum JG, van Zwieten BJ, Wohlfarth T, et al. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry. 2003;60(4):365-368. doi:10.101/archpsyc.60.4.365 (Pubitemid 36402996)
16. Storosum JG, Wohlfarth T, Gispen-de Wied CC, et al. Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. Am J Psychiatry. 2005;162(4): 799-802. doi:10.176/api.ajp.162.4.79 PubMed (Pubitemid 40489148)
17. Aguilar EJ, Siris SG. Do antipsychotic drugs influence suicidal behavior in schizophrenia? Psychopharmacol Bull. 2007;40(3):128-142. PubMed
18. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3): 332-339. doi:10.101/archpsyc.63.3.32 PubMed (Pubitemid 43345358)
19. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880. doi:10.136/bmj.b280 PubMed
20. Beasley CM Jr, Ball SG, Nilsson ME, et al. Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. J Clin Psychopharmacol. 2007;27(6):682-686. doi:10.1097/jcp.0b013e31815abf21 PubMed (Pubitemid 351339457)
21. Tauscher-Wisniewski S, Disch D, Plewes J, et al. Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Psychol Med. 2007; 37(11):1585-1593. doi:10.1017/S032917070146 PubMed (Pubitemid 47606853)
22. Vanderburg DG, Batzar E, Fogel I, et al. A pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. J Clin Psychiatry. 2009;70(5):674-683. doi:10.408/JCP.07m0404 PubMed
23. Thompson TR, Dudley TK, Nanry KP. Analysis of suicidal ideation and behavior in lamotrigine clinical trials. Poster presented at the 48th Annual NCDEU Meeting; May 27-39, 2008; Phoenix, Arizona.
24. Philip G, Hustad C, Noonan G, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):691-696, e6. doi:10.1016/j.jaci.209.08.010 PubMed
25. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47(2):209-218. doi:10.1097/chi.0b013e31815d8b2 PubMed (Pubitemid 351158789)
26. Stone MB, Jones ML. Clinical review: Relationship between antidepressant drugs and suicidality in adults. Pages 11-74. http://www.fda.gov/ohrms/dockets/ ac/06/briefing/2006-4272b1-01-FDA.pdf. Updated November 17, 2006. Accessed March 09, 2010.
27. Levenson M. Statistical review and evaluation: antiepileptic drugs and suicidality. Pages 7-50. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008- 4372b1-01-FDA-Katz.pdf. Updated May 23, 2008. Accessed January 21, 2011.
28. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043. doi:10.176/api.ajp.164.7.1035 PubMed (Pubitemid 47121392)
29. Stephens JH, Richard P, McHugh PR. Long-term follow-up of patients hospitalized for schizophrenia, 1913 to 1940. J Nerv Ment Dis. 1997; 185(12):715-721. doi:10.1097/05053-197120-01 PubMed
30. Healy D, Harris M, Tranter R, et al. Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. Br J Psychiatry. 2006;188(3):223-228. doi:10.192/bjp.18.3.23 PubMed
31. Heilä H, Isometsä ET, Henriksson MM, et al. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry. 1999;60(3):200-208. doi:10.408/JCP.v60n031 PubMed (Pubitemid 29168697)
32. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423-424. doi:10.102/pds.837 PubMed (Pubitemid 36903380)
33. Khan A, Kolts RL, Brodhead AE, et al. Suicide risk analysis among patients assigned to psychotropics and placebo. Psychopharmacol Bull. 2006;39(1):6-14. PubMed
34. Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91. doi:10.101/archpsyc.60.1.82 PubMed
35. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73(2-3):139-145. doi:10.1016/j.schres.204. 05.015 PubMed (Pubitemid 40103558)
36. Clozaril approved for reducing risk of suicide. FDA Consum. 2003; 37(2):5. PubMed
37. Scholten MR, Selten JP. Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug. Ned Tijdschr Geneeskd. 2005;149(41):2296-2298. PubMed
38. Slooff CJ, Arends J. Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug. Ned Tijdschr Geneeskd. 2006;150(7):400-401, author reply 401. PubMed
39. Beers E, Loonen AJ, Van Grootheest AC. Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug. Ned Tijdschr Geneeskd. 2006;150(7):401-402. PubMed
40. Holzer L, Eap CB. Aripiprazole and suicidality. Int Clin Psychopharmacol. 2006;21(2):125-126. doi:10.1097/01.yic.0185024.3032.86 PubMed (Pubitemid 43740321)
41. Zisook S, Kasckow JW, Lanouette NM, et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J Clin Psychiatry. 2010;71(7):915-922. doi:10.408/JCP.09m0569gre PubMed
42. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior part 3: impact of antipsychotics. J Affect Disord. 2007;103(1-3): 23-28. doi:10.1016/j.jad.207.05.018 PubMed (Pubitemid 47445780)
43. Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry. 2008;69(6):916-922. doi:10.408/JCP.v69n0605 PubMed (Pubitemid 351944943)
44. Baker RW, Brown E, Akiskal HS, et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry. 2004;185(6):472-478. doi:10.192/bjp.185.6.472 PubMed
45. Preti A, Meneghelli A, Pisano A, et al; Programma 2000 Team. Risk of suicide and suicidal ideation in psychosis: results from an Italian multimodal pilot program on early intervention in psychosis. Schizophr Res. 2009;113(2-3):145-150. doi:10.1016/j.schres.209.06.07 PubMed
46. DelBello M, Grcevich S. Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical anti-psychotics. J Clin Psychiatry. 2004;65(suppl 6):12-19. PubMed
47. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry. 2004; 65(suppl 6):30-44. PubMed
48. Fleischhaker C, Heiser P, Hennighausen K, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol. 2006;16(3):308-316. doi:10.1089/cap.206.16.308 PubMed (Pubitemid 43902427)
49. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008; 165(11):1420-1431. doi:10.176/api.ajp.208.08050756 PubMed
50. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, et al. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009;70(2):247-258. doi:10.408/JCP.08m03538 PubMed
51. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55-68. doi:10.2307/2530643 PubMed
52. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)9046-2 PubMed (Pubitemid 17189972)
53. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25(4):301-310. doi:10.1097/01.jcp.0169068.3432.70 PubMed (Pubitemid 41065070)
54. Brent D. Antidepressants and suicidal behavior: cause or cure? Am J Psychiatry. 2007;164(7):989-991. doi:10.176/api.ajp.164.7.989 PubMed
55. Klein DF. The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology. 2006;31(4):689-699. doi:10.1038/sj.np.13096 PubMed
56. Möller HJ. Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2006;256(8):476-496. doi:10.107/s0406-06-0689-8 PubMed
57. Posner K, Melvin GA, Stanley B, et al. Factors in the assessment of suicidality in youth. CNS Spectr. 2007;12(2):156-162. PubMed
58. DSM-5 proposed revisions includes new risk syndromes and suicide risk assessment tool [news release]. Arlington, VA: American Psychiatric Association; February 10, 2010. http://www.dsm5.org/Newsroom/Documents/Suicide%20Scale- Risk%20Syndrome%20release%20 FINAL%202.05.pdf. Accessed January 31, 2011.
59. ERT offers a new self-rated version of the C-SSRS, facilitating prospective suicidality monitoring.http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM225130.pdf. Accessed February 3, 2011